Literature DB >> 17546053

The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.

K Cheng1, S Grisendi, J G Clohessy, S Majid, R Bernardi, P Sportoletti, P P Pandolfi.   

Abstract

Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as the most frequent genetic alteration in acute myelogenous leukemia. However, the oncogenic potential of this nucleophosmin mutant (NPMc+) has never been established, which casts doubt on its role in leukemogenesis. By performing classical transformation assays, we find that NPMc+, but not wild-type NPM, cooperates specifically with adenovirus E1A to transform primary mouse embryonic fibroblasts in soft agar. We demonstrate that NPMc+ blocks the p19(Arf) (Arf) induction elicited by E1A. Surprisingly, however, we find that NPMc+ induces cellular senescence and that E1A is able to overcome this response. We propose a model whereby the NPMc+ pro-senescence activity needs to be evaded for oncogenic transformation, even though NPMc+ can concomitantly blunt the Arf/p53 pathway. These findings identify for the first time NPMc+ as an oncogene and shed new unexpected light on its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546053     DOI: 10.1038/sj.onc.1210549

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription.

Authors:  Karl Holmberg Olausson; Monica Nistér; Mikael S Lindström
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

2.  Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.

Authors:  Delin Chen; Jing Shan; Wei-Guo Zhu; Jun Qin; Wei Gu
Journal:  Nature       Date:  2010-03-07       Impact factor: 49.962

3.  The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Authors:  Ke Cheng; Paolo Sportoletti; Keisuke Ito; John G Clohessy; Julie Teruya-Feldstein; Jeffery L Kutok; Pier Paolo Pandolfi
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

4.  Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.

Authors:  Herschel Mukherjee; Kok-Ping Chan; Vibeke Andresen; Mariah L Hanley; Bjørn Tore Gjertsen; Andrew G Myers
Journal:  ACS Chem Biol       Date:  2015-01-05       Impact factor: 5.100

5.  Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.

Authors:  Niccolò Bolli; Elspeth M Payne; Clemens Grabher; Jeong-Soo Lee; Adam B Johnston; Brunangelo Falini; John P Kanki; A Thomas Look
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

6.  Reactivating the ARF-p53 axis in AML cells by targeting ULF.

Authors:  Delin Chen; Jong-Bok Yoon; Wei Gu
Journal:  Cell Cycle       Date:  2010-08-11       Impact factor: 4.534

Review 7.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

8.  Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies.

Authors:  Gerald Wertheim; Adam Bagg
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

9.  Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia.

Authors:  Todd S Laughlin; Michael W Becker; Jane L Liesveld; Deborah A Mulford; Camille N Abboud; Patrick Brown; Paul G Rothberg
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

10.  Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.

Authors:  João Agostinho Machado-Neto; Fabiola Traina; Mariana Lazarini; Paula de Melo Campos; Katia Borgia Barbosa Pagnano; Irene Lorand-Metze; Fernando Ferreira Costa; Sara T Olalla Saad
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.